GRB2 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, bosutinib, a tyrosine kinase inhibitor, is perhaps the best candidate identified, as it is already in use against chronic myeloid leukemia [108] and was found to target five upregulated proteins (CDC37, CDKN1B, GRB2, RASSF1, and SMAD2).